Rare diseases
Investigational molecules
Locations
3611 Valley Centre Drive Suite 300, 92130-3331, United States
Travere Therapeutics Inc. supports research in proteinuric glomerular diseases, with emphasis on focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), IgA nephropathy (IgAN), IgA vasculitis (IgAV), and Alport syndrome. Its studies focus on renal protection, reduction of proteinuria, and preservation of kidney function.
Research activity in this area reflects a strong therapeutic interest in chronic glomerular disease and related kidney injury.
Travere Therapeutics Inc. runs clinical trials in conditions such as Homocystinuria, IgA nephropathy, Focal segmental glomerulosclerosis, Glomerulonephritis minimal lesion, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.
BelgiumStudy on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases
GermanySafety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)
FranceStudy on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)
BelgiumStudy on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
